Terms: = Thyroid cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Prognosis
12 results:
1. LncRNA EILA promotes cdk4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein.
Cai Z; Shi Q; Li Y; Jin L; Li S; Wong LL; Wang J; Jiang X; Zhu M; Lin J; Wang Q; Yang W; Liu Y; Zhang J; Gong C; Yao H; Yao Y; Liu Q
Sci Adv; 2023 Oct; 9(40):eadi3821. PubMed ID: 37801505
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of Social Vulnerability in Pediatric Head and Neck cancer Care and prognosis in the United States.
Fei-Zhang DJ; Chelius DC; Patel UA; Smith SS; Sheyn AM; Rastatter JC
JAMA Netw Open; 2023 Feb; 6(2):e230016. PubMed ID: 36800183
[TBL] [Abstract] [Full Text] [Related]
3. Increased trend of thyroid cancer in childhood over the last 30 years in EU countries: a call for the pediatric surgeon.
Spinelli C; Ghionzoli M; Oreglio C; Sanna B; De Napoli L; Morganti R; Antonelli A; Morabito A; Miccoli P
Eur J Pediatr; 2022 Nov; 181(11):3907-3913. PubMed ID: 36044066
[TBL] [Abstract] [Full Text] [Related]
4. Surveillance, Epidemiology, and End Results Database update for pediatric thyroid carcinomas incidence and survival trends 2000-2016.
Tawde A; Jeyakumar A
Int J Pediatr Otorhinolaryngol; 2022 Feb; 153():111038. PubMed ID: 34998202
[TBL] [Abstract] [Full Text] [Related]
5. Papillary thyroid cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease.
Bongers PJ; Kluijfhout WP; Verzijl R; Lustgarten M; Vermeer M; Goldstein DP; Devon K; Rotstein LE; Asa SL; Brierley JD; Tsang RW; Ezzat S; Vriens MR; Mete O; Pasternak JD
Ann Surg Oncol; 2019 Aug; 26(8):2533-2539. PubMed ID: 31115855
[TBL] [Abstract] [Full Text] [Related]
6. MiR-128-3p suppresses breast cancer cellular progression via targeting LIMK1.
Zhao J; Li D; Fang L
Biomed Pharmacother; 2019 Jul; 115():108947. PubMed ID: 31078043
[TBL] [Abstract] [Full Text] [Related]
7. MicroRNA-791 is an independent prognostic factor of papillary thyroid carcinoma and inhibits the proliferation of PTC cells.
Gao XB; Chen CL; Tian ZL; Yuan FK; Jia GL
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5562-5568. PubMed ID: 30229829
[TBL] [Abstract] [Full Text] [Related]
8. MiR-519d-3p suppresses breast cancer cell growth and motility via targeting LIM domain kinase 1.
Li D; Song H; Wu T; Xie D; Hu J; Zhao J; Shen Q; Fang L
Mol Cell Biochem; 2018 Jul; 444(1-2):169-178. PubMed ID: 29188531
[TBL] [Abstract] [Full Text] [Related]
9. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract] [Full Text] [Related]
10. Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature.
Schaefer IM; Sahlmann CO; Overbeck T; Schweyer S; Menke J
BMC Cancer; 2012 Sep; 12():424. PubMed ID: 23006472
[TBL] [Abstract] [Full Text] [Related]
11. Multifocality of thyroid carcinomas: a "privilege" of papillary tumors or not?
Papageorgiou MS; Liratzopoulos N; Efremidou EI; Karanikas M; Minipoulos G; Manolas KJ
G Chir; 2010; 31(1-2):20-3. PubMed ID: 20298661
[TBL] [Abstract] [Full Text] [Related]
12. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract] [Full Text] [Related]
